MARKET

YMTX

YMTX

Yumanity Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.40
-0.08
-0.43%
Closed 16:00 02/24 EST
OPEN
18.50
PREV CLOSE
18.48
HIGH
18.95
LOW
18.09
VOLUME
84.08K
TURNOVER
--
52 WEEK HIGH
40.00
52 WEEK LOW
16.27
MARKET CAP
187.57M
P/E (TTM)
-1.2312
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021
Benzinga · 02/10 17:02
Yumanity Initiates Dosing in Phase 1B Study in Parkinson's Disease Trial
MT Newswires · 02/10 15:43
Yumanity Therapeutics provides update on lead Parkinson’s disease clinical program
Yumanity Therapeutics (YMTX) announces that dosing has started in its Phase 1b trial of YTX-7739 in patients with Parkinson’s Disease with preliminary results expected by mid 2021.YTX-7739, Yumanity's lead clinical-stage program, is
Seekingalpha · 02/10 13:23
Yumanity Therapeutics Provides Update on Its Lead Parkinson's Disease Clinical Program, YTX-7739
Results reported of the single ascending dose study in healthy volunteers
GlobeNewswire · 02/10 13:00
Yumanity Therapeutics Files Shelf of Up to About 1.5 Million Common Shares on Behalf of Selling Stockholders
MT Newswires · 02/04 03:33
BRIEF-Yumanity Therapeutics Inc Files For Shelf Of Up To 1.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
reuters.com · 02/03 22:23
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer...
GlobeNewswire · 01/06 13:00
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer...
GlobeNewswire · 01/06 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of YMTX. Analyze the recent business situations of Yumanity Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average YMTX stock price target is 98.00 with a high estimate of 160.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 23.13M
% Owned: 226.93%
Shares Outstanding: 10.19M
TypeInstitutionsShares
Increased
5
25.97K
New
30
2.51M
Decreased
12
13.47K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.91%
Pharmaceuticals & Medical Research
+1.08%
Key Executives
Chairman/Executive Board
N. Anthony Coles
President/Chief Executive Officer/Director
Richard Peters
Chief Financial Officer
Paulash Mohsen
Chief Accounting Officer
Marie Epstein
Chief Scientific Officer
Benito Munoz
Other
Geoffrey Gilmartin
Director
Patricia Allen
Director
Richard Heyman
Director
Cecil Pickett
Director
Lynne Zydowsky
Independent Director
David Arkowitz
Independent Director
Kimberlee Drapkin
Independent Director
Jeffery Kelly
  • Dividends
  • Splits
  • Insider Activity
No Data
About YMTX
Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company’s pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

Webull offers kinds of Yumanity Therapeutics Inc stock information, including NASDAQ:YMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading YMTX stock methods without spending real money on the virtual paper trading platform.